Most Read Research, BioBeats Resend + Trivia Answers

Research evidence excerpt

Most Read Research, BioBeats Resend + Trivia Answers

Biotechnology

EQUITY RESEARCH Industry Report

June 7, 2026

Most Read Research, BioBeats Resend + Trivia

Prices are as of 06/05/26. Answers Research Analysts:

Josh Schimmer

310-282-6513 What an exciting ASCO...but there was a bunch more happening this week

Josh.Schimmer@cantor.com as well - which we cover in this week's BioBeats.

Eric Schmidt

212-294-7724 Click HERE for the link to the recording or open this report for the slides. Eric.Schmidt@cantor.com

Prakhar Agrawal

212-610-3614 BioBeats Trivia: ABVX initially evaluated obefazimod for HIV.

Prakhar.Agrawal@cantor.com

●ABVX CEO Marc de Garidel was previously CEO of Cincor (sold to AZN) Olivia Brayer Saunders

212-428-5907 and Corvida (sold to Novo). He was also CEO of Ipsen from 2010-2016.

Olivia.Brayer@cantor.com

Carter Gould Most-Read Cantor Reports This Week

212-915-1794

Carter.Gould@cantor.com

●Weekend Musing - Humility HERE Kristen Kluska

212-915-1927 ●BioBUZZ- Take That, Cancer HERE Kristen.Kluska@cantor.com

Imogen Mansfield ●BioBuZZ - Oncology & other Chatter HERE

929-545-6495

Imogen.Mansfield@cantor.com ●SMMT: Breaking Down What Matters (Breakfast) HERE

Steve Seedhouse

212-915-1240 ●ADA- Key Obesity Datasets & Our Expectations HERE

Steve.Seedhouse@cantor.com

Yanni Souroutzidis ●SMMT: HARMONi-6 OS Benefit Strong HERE

929-730-2656

Yanni.Souroutzidis@cantor.com ●Takeaways from ASCO Lung & H&N KOL Breakfast HERE

Pete Stavropoulos, Ph.D. ●FULC to Discontinue Pociredir in SCD HERE 212-915-1966

Pete.Stavropoulos@cantor.com ●IMCR - TEME-AM In Focus At Breakfast This AM HERE

Li Watsek

212-915-1221

Li.Watsek@cantor.com Ahead Next Week:

●Thursday, June 11: Cantor hosting Private Company Webinar with

Astoria (register HERE)

Please see